772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)

Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772
Authors:
Manish Sharma
Deanne Lathers
Melissa M. Johnson
Jason J. Luke
Igor Puzanov
Brendan D. Curti
Christopher S. Chen
Anthony B. El-Khoueiry
Brian S. Henick
Margaret K. Callahan
Mario Sznol
Sandip Pravin Patel
Dawn K. Wilson
Melissa Ricker
Lizhi Cao
Pushpa Jayaraman
Jenny Che
Li Peng
David Feltquate
Deanne Lathers
Anthony W. Tolcher
Affiliated Authors:
Brian S. Henick
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-sitc2022.0772
Publication Date:
Data Source:
OpenAlex

Record Created: